$3.30
+0.09 (+2.80%)
Open$3.31
Previous Close$3.21
Day High$3.32
Day Low$3.20
52W High$7.20
52W Low$3.75
Volume—
Avg Volume11.7K
Market Cap7.78M
P/E Ratio—
EPS$-16.34
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+699.1% upside
Current
$3.30
$3.30
Target
$26.37
$26.37
$21.16
$26.37 avg
$30.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.95M | 7.20M | 3.98M |
| Net Income | -34,468,068 | -28,116,796 | 267.7K |
| Profit Margin | -433.7% | -412.1% | 6.7% |
| EBITDA | -35,961,390 | -30,964,670 | 477.9K |
| Free Cash Flow | — | — | 225.1K |
| Rev Growth | +10.3% | +10.3% | +11.2% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |